ClinicalTrials.gov record
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
ACTIVE NOT RECRUITING · NCT03277638
Trial record
NCT IDNCT03277638
Status
ACTIVE NOT RECRUITING
Study type
INTERVENTIONAL
Phase
PHASE1, PHASE2
Enrollment
32
Conditions
Glioblastoma, Adult
Interventions
Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post, Laser Interstitial Thermotherapy
Locations
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Indexed topics
Last update
2026-06-25